Currently Empty: ₾0.00
In this section, we will explore real-life clinical cases and learn together how to approach them based on the latest international guidelines. Each case is designed to enhance your clinical thinking, strengthen your diagnostic skills, and guide you step by step in making the right decisions in real practice.
Together with Dr. Israa Tarek, we will break down each case in a simple, structured, and practical way—focusing not only on the diagnosis, but also on management, clinical reasoning, and key takeaways that every medical student and doctor should know.
This is more than just case discussion; it is an interactive learning experience where you will think, analyze, and grow your confidence in handling real clinical situations.
Join us as we connect theory to practice and learn how to think like a doctor.
Course Content
Pseudobulbar Affect (PBA)
Pseudobulbar Affect (PBA) is a neurological disorder characterized by sudden, involuntary, and uncontrollable episodes of laughing or crying that are inappropriate or exaggerated compared with the patient’s actual emotional state. The emotional expression often does not match the true underlying mood. Patients may cry without feeling sad or laugh without feeling happy, and the episodes are usually brief but repetitive and socially distressing. PBA is most commonly associated with neurological diseases affecting the brain pathways responsible for emotional regulation, including stroke, multiple sclerosis, amyotrophic lateral sclerosis (ALS), traumatic brain injury, Parkinson disease, Alzheimer disease, and other neurodegenerative disorders.
The pathophysiology of PBA involves disruption of the neural circuits that regulate emotional expression, particularly the corticobulbar pathways connecting the frontal cortex, limbic system, cerebellum, and brainstem. Normally, these pathways provide inhibitory control over emotional responses. Damage to these regions leads to loss of inhibition and abnormal emotional expression, resulting in exaggerated laughing or crying episodes. Neurotransmitters such as serotonin, glutamate, and dopamine are involved in the process, which explains the effectiveness of serotonergic agents and glutamate-modulating medications in treatment.
Clinically, patients present with sudden episodes of crying or laughing that are involuntary, difficult to suppress, and disproportionate to the triggering stimulus. Episodes may occur without any clear trigger and usually last from seconds to several minutes. Emotional outbursts are often embarrassing for patients and may significantly impair social interactions and quality of life. Importantly, unlike depression, the patient’s underlying mood is often normal between episodes. Associated neurological signs depend on the underlying disease and may include dysarthria, dysphagia, hyperreflexia, spasticity, muscle weakness, ataxia, or cognitive impairment.
Diagnosis of PBA is primarily clinical and requires careful differentiation from psychiatric conditions such as depression, bipolar disorder, anxiety disorders, or personality disorders. In depression, crying is usually associated with persistent low mood, sleep disturbance, reduced appetite, and loss of interest, whereas in PBA the episodes are brief, sudden, and incongruent with mood. A detailed neurological history and examination are essential. The Center for Neurologic Study–Lability Scale (CNS-LS) may be used as a screening tool to assess severity and frequency of symptoms. Imaging studies such as MRI brain are useful to identify underlying neurological pathology including stroke, demyelination, or neurodegenerative changes.
Management involves both treatment of the underlying neurological disease and symptomatic control of emotional episodes. Patient and family education are important to explain that the condition is neurological rather than psychiatric and that emotional outbursts are involuntary. Psychological support and coping strategies may help reduce social embarrassment and anxiety.
The most effective pharmacological treatment is the combination of dextromethorphan and quinidine, available as Nuedexta. Dextromethorphan acts as an NMDA receptor antagonist and sigma-1 receptor agonist, modulating glutamate-mediated neurotransmission involved in emotional expression. Quinidine inhibits hepatic metabolism of dextromethorphan through CYP2D6 inhibition, thereby increasing its bioavailability. This combination significantly reduces the frequency and severity of emotional episodes. Common side effects include dizziness, diarrhea, fatigue, and QT interval prolongation, therefore caution is required in patients with cardiac arrhythmias or prolonged QT syndrome.
Selective serotonin reuptake inhibitors such as Sertraline, Fluoxetine, and Citalopram may also be beneficial, particularly in patients with coexisting depressive symptoms. Tricyclic antidepressants such as Amitriptyline are less commonly used because of their anticholinergic and cardiovascular side effects.
A typical clinical scenario involves a patient with a previous stroke or ALS who develops sudden episodes of uncontrollable crying despite denying sadness or depression. Recognition of the condition is important because appropriate treatment can significantly improve emotional control, social functioning, and quality of life.
-
Pseudobulbar Affect (PBA) Clinical Case presentation
Dilated Cardiomyopathy (DCM)
Dilated Cardiomyopathy (DCM) is a myocardial disease characterized by dilation of one or both ventricles associated with impaired systolic function and reduced myocardial contractility. It is one of the most common forms of cardiomyopathy and a major cause of heart failure and sudden cardiac death. The condition results in enlargement of the ventricular chambers, particularly the left ventricle, leading to decreased ejection fraction and progressive inability of the heart to pump blood effectively.
DCM may be idiopathic or secondary to various genetic, infectious, toxic, metabolic, autoimmune, or ischemic causes. Approximately 30–50% of cases are familial and linked to mutations affecting cytoskeletal, sarcomeric, or mitochondrial proteins. Common secondary causes include viral myocarditis, chronic alcohol use, chemotherapy agents such as doxorubicin, uncontrolled hypertension, ischemic heart disease, thyroid disorders, nutritional deficiencies, pregnancy-related cardiomyopathy, and infiltrative or inflammatory diseases. Viral infections such as Coxsackie B virus are classic infectious causes and may trigger myocardial inflammation followed by ventricular remodeling and fibrosis.
The pathophysiology involves myocardial injury leading to impaired contractility and reduced systolic function. In response to reduced cardiac output, compensatory neurohormonal mechanisms are activated, including the sympathetic nervous system and the renin–angiotensin–aldosterone system (RAAS). Initially these mechanisms maintain perfusion, but chronically they contribute to ventricular remodeling, chamber dilation, fibrosis, and worsening heart failure. Progressive ventricular enlargement increases wall stress according to the Law of Laplace, further impairing myocardial performance. Mitral or tricuspid regurgitation may develop secondary to annular dilation, and stagnant blood flow within dilated chambers increases the risk of thrombus formation and embolic events.
Patients commonly present with symptoms of congestive heart failure. Dyspnea is the most frequent symptom and initially occurs with exertion before progressing to dyspnea at rest. Orthopnea and paroxysmal nocturnal dyspnea reflect pulmonary congestion caused by elevated left ventricular filling pressures. Fatigue and exercise intolerance occur due to reduced cardiac output and poor tissue perfusion. Peripheral edema, abdominal distension, hepatomegaly, and ascites may develop in advanced right-sided heart failure. Palpitations are common because ventricular dilation predisposes to atrial and ventricular arrhythmias. Chest pain may occur even in the absence of coronary artery disease due to increased myocardial oxygen demand and wall stress. Syncope or presyncope raises concern for malignant arrhythmias or severe hemodynamic compromise.
Physical examination may reveal tachycardia, hypotension, elevated jugular venous pressure, displaced and diffuse apical impulse, bibasal crackles, peripheral edema, hepatomegaly, and cool extremities. Auscultation may demonstrate a third heart sound (S3 gallop), which is characteristic of volume overload and ventricular dysfunction. Functional mitral or tricuspid regurgitation murmurs may also be present.
Diagnosis is based on clinical findings and cardiac imaging. Echocardiography is the cornerstone investigation and typically demonstrates ventricular dilation with reduced systolic function and decreased left ventricular ejection fraction. It also evaluates chamber size, valvular regurgitation, intracardiac thrombi, and diastolic function. A reduced ejection fraction confirms impaired systolic performance.
EF = frac{Stroke Volume}{End Diastolic Volume} times 100
Electrocardiography may show sinus tachycardia, left bundle branch block, nonspecific ST-T wave changes, atrial fibrillation, or ventricular arrhythmias. Chest X-ray often demonstrates cardiomegaly and signs of pulmonary congestion or pleural effusions. Laboratory investigations include BNP or NT-proBNP, which are elevated in heart failure, and troponin levels if myocarditis or ischemia is suspected. Additional testing may include thyroid function tests, viral serology, iron studies, autoimmune screening, and genetic testing in familial cases. Cardiac MRI provides detailed assessment of myocardial fibrosis, inflammation, infiltrative disease, and tissue characterization, particularly when myocarditis or infiltrative cardiomyopathy is suspected. Coronary angiography may be required to exclude ischemic cardiomyopathy in selected patients.
Management focuses on treating heart failure, preventing disease progression, reducing mortality, and addressing the underlying cause whenever possible. Lifestyle modification includes sodium restriction, fluid management, alcohol cessation, smoking cessation, vaccination, and regular monitoring. Patients with advanced disease may require restriction of intense physical activity.
Pharmacological treatment follows guideline-directed therapy for heart failure with reduced ejection fraction. ACE inhibitors such as Enalapril or ARBs such as Losartan reduce afterload, inhibit ventricular remodeling, and improve survival. Beta blockers including Carvedilol and Metoprolol improve ventricular function and decrease mortality by reducing sympathetic overactivity. Mineralocorticoid receptor antagonists such as Spironolactone further reduce morbidity and mortality in symptomatic patients.
Diuretics such as Furosemide are used to control pulmonary and peripheral congestion. In selected patients, SGLT2 inhibitors such as Dapagliflozin have demonstrated significant benefit in heart failure outcomes. Anticoagulation may be indicated in patients with atrial fibrillation, previous thromboembolism, or intracardiac thrombus. Antiarrhythmic therapy may be necessary for symptomatic arrhythmias.
Patients with severe systolic dysfunction and high risk of sudden cardiac death may require implantation of an implantable cardioverter-defibrillator (ICD). Cardiac resynchronization therapy (CRT) is beneficial in patients with reduced ejection fraction and significant conduction delay such as left bundle branch block. In end-stage disease refractory to medical therapy, advanced options include ventricular assist devices or heart transplantation.
Complications of DCM include progressive heart failure, atrial fibrillation, ventricular tachyarrhythmias, thromboembolic events, cardiogenic shock, and sudden cardiac death. Prognosis depends on the underlying etiology, severity of ventricular dysfunction, response to treatment, and presence of arrhythmias. Early diagnosis and optimal medical therapy significantly improve survival and quality of life.
A typical clinical presentation involves a middle-aged patient presenting with progressive exertional dyspnea, orthopnea, fatigue, and lower limb edema. Echocardiography reveals dilated left ventricular chambers with markedly reduced ejection fraction, confirming the diagnosis of dilated cardiomyopathy.
-
DCM Clinical Case Presentation
00:56
Alice in Wonderland Syndrome (AIWS)
Alice in Wonderland Syndrome (AIWS) is a rare neuropsychological disorder characterized by transient episodes of distorted visual perception, altered body image, and disturbed sense of time or space. Patients experience perceptual distortions rather than true hallucinations, meaning they are usually aware that what they are seeing or feeling is not real. The syndrome was named after the novel Alice's Adventures in Wonderland because the symptoms resemble the unusual size and spatial distortions described in the story.
The condition most commonly affects children and adolescents, although adults may also develop the syndrome, particularly in association with migraines or neurological disease. Episodes are usually temporary and self-limited, lasting from minutes to hours, but recurrent attacks may occur depending on the underlying cause.
The pathophysiology is not completely understood, but it is believed to involve transient dysfunction of cortical regions responsible for visual processing and spatial perception, particularly the temporoparietal-occipital junction. Abnormal neuronal activity affecting visual association pathways leads to distorted integration of sensory information. Cerebral hypoperfusion during migraine aura, epileptic discharges, inflammatory processes, or infectious encephalitis may disrupt normal cortical perception and produce characteristic symptoms.
AIWS is strongly associated with migraine disorders, especially migraine with aura, and in many patients it may represent a type of migraine aura phenomenon. Viral infections are another major cause in children, particularly infection with Epstein–Barr virus causing infectious mononucleosis. Other infectious agents such as influenza, varicella, Coxsackie virus, and encephalitis have also been reported. Neurological disorders associated with AIWS include epilepsy, temporal or parietal lobe lesions, traumatic brain injury, stroke, brain tumors, encephalitis, and neurodegenerative diseases. Certain psychoactive substances and medications may occasionally trigger similar perceptual disturbances.
The hallmark of the syndrome is perceptual distortion. Patients may experience micropsia, in which objects appear abnormally small, or macropsia, where objects appear excessively large. Some perceive objects as unusually near or distant, known as pelopsia and teleopsia. Distortions may also affect body image, causing the patient to feel that parts of the body are enlarging, shrinking, elongating, or changing shape. Some patients describe feeling detached from their own body or experiencing altered movement sensations. Disturbance in time perception may occur, with time seeming excessively fast or slow. Episodes are often frightening, especially in children, although consciousness is usually preserved.
Visual distortions are commonly accompanied by symptoms related to the underlying disorder. Migraine-associated AIWS may present with headache, photophobia, nausea, or aura symptoms. Infectious causes may present with fever, fatigue, sore throat, lymphadenopathy, or encephalopathic symptoms. Seizure-related episodes may include altered awareness, automatisms, or postictal confusion.
Physical examination is often normal between episodes. Neurological examination may reveal findings related to the underlying disease such as focal deficits, meningeal irritation, or seizure activity. Mental status is generally preserved, which helps differentiate AIWS from psychosis or delirium.
Diagnosis is primarily clinical and based on characteristic perceptual symptoms together with exclusion of other neurological or psychiatric conditions. Careful history-taking is essential to identify migraine, infection, epilepsy, or medication triggers. There is no single diagnostic test specific for AIWS.
Investigations are guided by the suspected underlying cause. MRI brain may be performed to exclude structural lesions such as tumors, stroke, or demyelinating disease. Electroencephalography (EEG) is useful if epilepsy is suspected. Blood tests and viral studies may be indicated in infectious cases, particularly Epstein–Barr virus serology in children presenting with recent febrile illness. Neuroimaging and cerebrospinal fluid analysis may be necessary if encephalitis or central nervous system infection is suspected.
The differential diagnosis includes migraine aura, temporal lobe epilepsy, psychotic disorders, delirium, intoxication, schizophrenia, hallucinogen use, depersonalization disorder, and occipital lobe pathology. Unlike psychosis, patients with AIWS usually maintain insight that the perceptions are abnormal and unreal.
Management depends on treatment of the underlying condition. Reassurance is important because episodes are often self-limited and benign, especially in children. Migraine-associated AIWS is managed with migraine prophylaxis and trigger avoidance. Antiepileptic therapy is indicated when seizures are identified. Infectious causes are treated supportively or with appropriate antimicrobial therapy when necessary. Adequate sleep, stress reduction, hydration, and avoidance of precipitating factors may help reduce recurrence.
There is no specific medication universally used for AIWS itself. In migraine-related cases, medications such as Topiramate, Propranolol, or Amitriptyline may reduce attacks. Seizure-related cases require appropriate antiepileptic drugs depending on seizure type.
The prognosis is generally good, particularly in children, where episodes often resolve spontaneously with age or after treatment of the underlying trigger. Chronic or recurrent symptoms may occur in patients with persistent migraine or epilepsy. Serious prognosis depends mainly on the underlying neurological disorder rather than the syndrome itself.
A classic clinical scenario involves a child with recent viral illness or migraine history who suddenly reports that objects in the room appear extremely small or far away while remaining fully conscious and aware that the perception is abnormal. The symptoms resolve spontaneously after several minutes without residual neurological deficit.
-
AIWS Clinical case presentation
00:32
“Silent” heart attack
Patients with Type 2 Diabetes may develop a “silent” heart attack with little or no chest pain because diabetic neuropathy can impair pain sensation. Instead of typical crushing chest pain, patients may present with fatigue, shortness of breath, sweating, nausea, dizziness, or mild chest discomfort. These symptoms should never be ignored, as delayed diagnosis increases the risk of serious complications and death. Early recognition and prompt medical evaluation are essential to improve outcomes and save lives.
-
“Silent” heart attack Clinical case presentation
00:51
Vitamin B12 deficiency
Vitamin B12 deficiency can affect both the blood and nervous system, leading to a wide range of symptoms. Common manifestations include fatigue, weakness, pallor, shortness of breath, and palpitations due to megaloblastic anemia. Patients may also develop glossitis with a red, painful tongue.
Neurological symptoms are especially important and may include peripheral neuropathy causing numbness and tingling in the hands and feet, loss of vibration and proprioception sensation, sensory ataxia with unsteady gait, and a positive Romberg sign. Proprioception is the ability to sense the position of body parts without looking at them.
Neuropsychiatric symptoms may include memory impairment, poor concentration, confusion, depression, and irritability. Severe prolonged deficiency can lead to subacute combined degeneration of the spinal cord, affecting the posterior columns and corticospinal tracts, which may cause irreversible neurological damage if untreated.
Early diagnosis and treatment with Vitamin B12 are essential to prevent permanent complications.
-
Vitamin B12 deficiency Clinical case presentation
03:02
A course by
IT
Lessons: